BIIA 0388

Drug Profile

BIIA 0388

Alternative Names: BIIA388C1

Latest Information Update: 14 Jun 2001

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Neuroprotectants
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cerebral ischaemia; Epilepsy

Most Recent Events

  • 14 Jun 2001 No-Development-Reported for Epilepsy in Germany (Unknown route)
  • 14 Jun 2001 No-Development-Reported for Cerebral ischaemia in Germany (Unknown route)
  • 17 Jan 2000 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top